Gilead Sciences earnings date and guidance

Gilead Sciences expects its next results on October 29, 2026. Watch whether Yeztugo is becoming a repeat business.

What has Gilead Sciences guided for the year?

Gilead’s weighted path is a 15% loss by October 2027 and a 1% gain by October 2029, hinging on durable HIV cash flow and returns from new products and acquisitions. Management guides to 2026 product sales of $30,100–$30,400 million. It expects HIV sales growth of 9%–10% and Yeztugo sales of $1,000 million. Guidance also carries diluted loss per share of $3.75–$3.40 against illustrative non-GAAP diluted EPS of $8.50–$8.85.

What trend do Gilead Sciences' recent results show?

Revenue reached $7,803 million, compared with $7,082 million a year earlier. Reported growth was 10.2%, but $156 million came from recognizing previously constrained intellectual-property sale revenue. Excluding that item, revenue was $7,647 million and growth was 8.0%. The accounting release concerned an earlier transaction, not new Biktarvy, Trodelvy or Yeztugo demand.

The reported net loss was $10,496 million. Acquired research included approximately $7,000 million for one program and $3,100 million for another. A third acquired program added approximately $1,900 million. An $860 million Lakefront reimbursement reduced acquired-research expense rather than appearing as revenue. Trodelvy also suffered a further $1,750 million impairment. These items explain why adjusted EPS remained negative at $6.75, even though management illustrated approximately $2.27 after excluding the acquisitions and other non-recurring items.

What should Gilead Sciences watchers look for next?

The next quarterly report should test Yeztugo’s progress toward its annual target and show whether cell-therapy sales are stabilizing. Operating cash generation and debt reduction matter just as much as reported earnings.